These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 16979437)

  • 21. Ongoing investigations and new uses of radioimmunotherapy in the treatment of non-Hodgkin's lymphoma.
    Meredith RF
    Int J Radiat Oncol Biol Phys; 2006; 66(2 Suppl):S23-9. PubMed ID: 16979435
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of ibritumomab tiuxetan anti-CD20 radioimmunotherapy in a non-Hodgkin's lymphoma patient previously treated with a yttrium-90-labeled anti-CD22 monoclonal antibody.
    Tsai DE; Maillard I; Schuster SJ; Nasta SD; Porter DL; Klumpp TR; Goldenberg DM; Luger SM; Alavi A; Sharkey RM; Hartzell KB; Stadtmauer EA
    Clin Lymphoma; 2003 Jun; 4(1):56-9. PubMed ID: 12837157
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma.
    Gordon LI; Witzig T; Molina A; Czuczman M; Emmanouilides C; Joyce R; Vo K; Theuer C; Pohlman B; Bartlett N; Wiseman G; Darif M; White C
    Clin Lymphoma; 2004 Sep; 5(2):98-101. PubMed ID: 15453924
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ibritumomab tiuxetan for non-Hodgkin's lymphoma.
    Johnston PB; Bondly C; Micallef IN
    Expert Rev Anticancer Ther; 2006 Jun; 6(6):861-9. PubMed ID: 16761929
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Logistics of radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin).
    Zimmer AM
    Semin Nucl Med; 2004 Jan; 34(1 Suppl 1):14-9. PubMed ID: 14762740
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Report of a European consensus workshop to develop recommendations for the optimal use of (90)Y-ibritumomab tiuxetan (Zevalin) in lymphoma.
    Hagenbeek A; Lewington V
    Ann Oncol; 2005 May; 16(5):786-92. PubMed ID: 15802280
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical development of radioimmunotherapy for B-cell non-Hodgkin's lymphoma.
    Meredith RF; Knox SJ
    Int J Radiat Oncol Biol Phys; 2006; 66(2 Suppl):S15-22. PubMed ID: 16979433
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Radioimmunotherapy for NHL: experience of 90Y-ibritumomab tiuxetan in clinical practice.
    Hagenbeek A
    Leuk Lymphoma; 2003; 44 Suppl 4():S37-47. PubMed ID: 15154741
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 90Y-ibritumomab tiuxetan: rationale for patient selection in the treatment of indolent non-Hodgkin's lymphoma.
    Grillo-López AJ
    Semin Oncol; 2005 Feb; 32(1 Suppl 1):S44-9. PubMed ID: 15786025
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High-dose yttrium-90-ibritumomab tiuxetan with tandem stem-cell reinfusion: an outpatient preparative regimen for autologous hematopoietic cell transplantation.
    Devizzi L; Guidetti A; Tarella C; Magni M; Matteucci P; Seregni E; Chiesa C; Bombardieri E; Di Nicola M; Carlo-Stella C; Gianni AM
    J Clin Oncol; 2008 Nov; 26(32):5175-82. PubMed ID: 18854569
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Follow-up results of a phase II study of ibritumomab tiuxetan radioimmunotherapy in patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma and mild thrombocytopenia.
    Schilder R; Molina A; Bartlett N; Witzig T; Gordon L; Murray J; Spies S; Wang H; Wiseman G; White C
    Cancer Biother Radiopharm; 2004 Aug; 19(4):478-81. PubMed ID: 15453962
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of radioimmunotherapy with yttrium-90 ibritumomab tiuxetan in the treatment of non-Hodgkin lymphoma.
    Cheson BD
    BioDrugs; 2005; 19(5):309-22. PubMed ID: 16207072
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Selecting patients for treatment with 90Y ibritumomab tiuxetan (Zevalin).
    Gregory SA
    Semin Oncol; 2003 Dec; 30(6 Suppl 17):17-22. PubMed ID: 14710399
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nursing a patient during and after 90Y-ibritumomab tiuxetan (Zevalin) therapy.
    Clayton J
    Leuk Lymphoma; 2003; 44 Suppl 4():S49-55. PubMed ID: 15154742
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and efficacy of radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin).
    Borghaei H; Schilder RJ
    Semin Nucl Med; 2004 Jan; 34(1 Suppl 1):4-9. PubMed ID: 14762738
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antilymphoma treatments given subsequent to Yttrium 90 ibritumomab tiuxetan are feasible in patients with progressive non-Hodgkin's lymphoma: a review of the literature.
    Ansell SM; Schilder RJ; Pieslor PC; Gordon LI; Emmanouilides C; Vo K; Czuczman MS; Witzig TE; Theuer C; Molina A
    Clin Lymphoma; 2004 Dec; 5(3):202-4. PubMed ID: 15636698
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Future directions in radioimmunotherapy for B-cell lymphoma.
    Horning SJ
    Semin Oncol; 2003 Dec; 30(6 Suppl 17):29-34. PubMed ID: 14710401
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Full-dose 90Y ibritumomab tiuxetan therapy is safe in patients with prior myeloablative chemotherapy.
    Jacobs SA; Vidnovic N; Joyce J; McCook B; Torok F; Avril N
    Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7146s-7150s. PubMed ID: 16203814
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphoma.
    Emmanouilides C; Witzig TE; Gordon LI; Vo K; Wiseman GA; Flinn IW; Darif M; Schilder RJ; Molina A
    Leuk Lymphoma; 2006 Apr; 47(4):629-36. PubMed ID: 16690521
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin).
    Riley MB; Gordon LI
    Semin Oncol Nurs; 2004 Feb; 20(1 Suppl 1):8-13. PubMed ID: 15160856
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.